INTRON A LIQUID

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

INTERFERON ALFA-2B

Pieejams no:

MERCK CANADA INC

ATĶ kods:

L03AB05

SNN (starptautisko nepatentēto nosaukumu):

INTERFERON ALFA-2B

Deva:

50000000UNIT

Zāļu forma:

LIQUID

Kompozīcija:

INTERFERON ALFA-2B 50000000UNIT

Ievadīšanas:

SUBCUTANEOUS

Vienības iepakojumā:

1.2ML

Receptes veids:

Prescription

Ārstniecības joma:

INTERFERONS

Produktu pārskats:

Active ingredient group (AIG) number: 0118647007; AHFS:

Autorizācija statuss:

CANCELLED POST MARKET

Autorizācija datums:

2018-12-14

Produkta apraksts

_INTRON A_
_®_
_ (interferon alfa-2b)_
_ _
_ _
_ _
_Page 1 of 46 _
PRODUCT MONOGRAPH
INTRON A
®
INTERFERON ALFA-2B
LYOPHILIZED POWDER WITH DILUENT:
10 million IU interferon alfa-2b/vial
18 million IU interferon alfa-2b/vial
READY-TO-USE SOLUTION (ALBUMIN (HUMAN) FREE):
10 million IU interferon alfa-2b/vial (10 million IU/mL)
18 million IU interferon alfa-2b/vial (6 million IU/mL)
25 million IU interferon alfa-2b/vial (10 million IU/mL)
SOLUTION FOR INJECTION (ALBUMIN (HUMAN) FREE), MULTI-DOSE PEN:
18 million IU interferon alfa-2b/pen (15 million IU/mL)
30 million IU interferon alfa-2b/pen (25 million IU/mL)
60 million IU interferon alfa-2b/pen (50 million IU/mL)
BIOLOGICAL RESPONSE MODIFIER
Merck Canada Inc.
Date of Revision:
16750 route Transcanadienne
December 14, 2016
Kirkland, Quebec H9H 4M7
Submission Control No: 204348
Date of Approval:
April 25, 2017
_INTRON A_
_®_
_ (interferon alfa-2b)_
_ _
_ _
_ _
_Page 2 of 46 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
DESCRIPTION...................................................................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
4
CONTRAINDICATIONS
..................................................................................................
6
WARNINGS AND PRECAUTIONS
.................................................................................
6
ADVERSE REACTIONS
.................................................................................................
13
DRUG INTERACTIONS
.................................................................................................
17
DOSAGE AND ADMINISTRATION
.............................................................................
18
OVERDOSAGE
...................................................................